Containing 95% Less Nicotine than Traditional Cigarettes, VLN
® is the Only Combustible Tobacco Product that Complies with the FDA’s Proposed Nicotine Cap
/EIN News/ WILLIAMSVILLE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it continues to be confident on the renewal of the FDA’s proposed reduced nicotine mandate that would make all cigarettes “minimally or non-addictive.” By way of support, four former U.S. Food and Drug Administration (FDA) commissioners, Robert M. Califf, M.D. MACC; Scott Gottlieb, M.D.; Peggy Hamburg, M.D.; and, Jane Henney, M.D., spoke on a recent panel and were vocal in their endorsement of the mandate to limit the amount of nicotine in cigarettes to levels already achieved by 22nd Century’s reduced nicotine content cigarettes, VLN
(1)
Newly founded online marketplace Elusive has received investment from private equity house Pinnacle
LONDON, UNITED KINGDOM / ACCESSWIRE / March 17, 2021 / Founded by 3 young entrepreneurs, Elusive aims to play a big part in the fast-growing luxury goods market. Their main focus will be reselling authentic limited edition footwear on their online platform and helping them become more accessible within Europe. As well as footwear, they will also look to stock the most sought after accessories including watches. Pinnacle owner and director
Steve Hibbert said, Bringing together 3 very talented young men under one company, all at the top of their game in this exciting marketplace was the goal of this exercise .
IGT, Authentic Brands Sign Multi-Year Deal For Elvis Presley Lottery Licensing Rights
LONDON (dpa-AFX) - Multinational gaming company International Game Technology Plc (IGT) said on Wednesday that it has signed a multi-year licensing deal with Authentic Brands Group or ABG to develop and distribute Elvis Presley-themed lottery games in the United States and Canada.
Entertainment company ABG is the global owner of the Elvis Presley brand.
As per the agreement, IGT will develop compelling instant tickets, entertaining draw-based games and attractive mobile and interactive games. The company will also focus on turnkey second-chance promotions and exciting offers for lottery clients and their players.
CN Bio introduces the PhysioMimix OOC Multi-Organ Microphysiological System
Expands portfolio of easy-to-use, robust and reliable human-relevant in vitro models, for fast-tracked drug discovery and development
System to be launched at Society of Toxicology s 2021 Virtual Annual Meeting, 12
th 26
th March 2021
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS. The next-generation platform combines CN Bio s
in vitro 3D liver model, whose phenotype and functions mimic that
in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a key milestone in the Company s mission to develop the most complete human body-on-a-chip in the laboratory, the PhysioMimix OOC Multi-Organ MPS will provide advanced insights into the potential effects of nov
(0)
Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, with the third SAD cohort actively dosing patients.
KAN-101, Anokion s lead antigen-specific drug product candidate, aims to re-educate immune cells to not respond to gluten antigens. The ACeD study is a randomized, double-blind, placebo-controlled Phase 1 trial that will enroll a total of up to 40 patients with celiac disease who are on a gluten free diet. The study is composed of two parts. In